β blockers | ACE inhibitors | Spironolactone | |
---|---|---|---|
Using baseline risk from local data rather than from the trials. Comparison of impacts of β blockers, ACE inhibitors, spironolactone on all cause mortality within one year of hospitalisation for congestive heart failure, using the baseline risk in the Australian (Hunter area) population. NNT is the reciprocal of the absolute risk reduction. Pe is the proportion of the population with disease eligible for the intervention. Pd is the proportion of the population with the disease. PIN has been rounded to the nearest 100 | |||
Baseline risk | 0.29 | 0.29 | 0.29 |
Relative risk reduction | 0.34 | 0.16 | 0.30 |
Absolute risk reduction | 0.0986 | 0.0464 | 0.087 |
NNT | 10.1 | 21.6 | 11.5 |
Pe | 0.75 | 0.75 | 0.73 |
Disease impact number (DIN) | 13.5 | 28.7 | 15.7 |
Pd | 0.0042 | 0.0042 | 0.0042 |
Population impact number (PIN) | 3200 | 6800 | 3700 |